Recent Updates
Recently added Catalysts

Etanercept Liquid

Phase 3

Rheumatoid Arthritis | Small molecule | Immunology |Amgen Inc.|Last Updated: Apr 26, 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment -

FDA Designations

No designations recorded

Clinical trial landscape

Etanercept Liquid · 1 trial · 1 indication

Phase 3 1
NCT00110903Treatment for Subjects With Active Rheumatoid Arthritis (RA)Rheumatoid Arthritis
COMPLETED- Analytics
PHASE3COMPLETED
Treatment for Subjects With Active Rheumatoid Arthritis (RA)
Rheumatoid ArthritisUnlock trial analytics

Study Endpoints

Primary Endpoints

Proportion of subjects having positive immunoassay response to etanercept liquid during the treatment period.

Secondary Endpoints

Incidence of adverse events, infectious episodes, serious adverse events, serious infectious episodes
Measurements from safety laboratory assessments.
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
Etanercept LiquidDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: - Fulfill the 1987 American Rheumatism Association (ARA) criteria for RA - Active RA at the time of enrollment, receipt of concomitant methotrexate at a dose of up to 25 mg a week is permitted - Screening lab results must demonstrate: * AST and ALT less than or equal to 2 times ...

Unlock Eligibility Criteria